Compare Impinj Inc (PI) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Impinj Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? Impinj Inc trades at $189.45 (market cap $5.60B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Impinj Inc and Travere Therapeutics Inc. Common Stock are close in size by market cap, and Impinj Inc is more actively traded (39,355 versus 1,668,577). Which is the better fit depends on your goals — on Pluang, investors hold Impinj Inc for 22 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| PI | TVTX | |
|---|---|---|
Market Cap | $5.60B | $4.88B |
Volume | 39,355 | 1,668,577 |
Sector | Technology | Health |
52-Week High | $241.91 | $67.52 |
52-Week Low | $91.34 | $26.79 |
Typical Hold Time | 22 Days | 0 Days |
Enterprise Value | $5.74B | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Impinj (PI) trades at $183.26, down 3.56% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 results with EPS of $0.86 beating estimates, though it operates at a net loss margin of -7.26%. Recent news highlights CEO optimism about growth in RFID tracking markets and upcoming Q3 earnings.
Outlook remains mixed: analyst consensus is bullish (73% buy ratings) with a $178.83 price target, but high valuation multiples and persistent losses pose risks. Key catalysts include Q3 earnings and execution in retail and logistics segments, while competition and margin pressure are concerns.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Impinj Inc
Impinj, Inc. is a leading provider of RAIN RFID (radio-frequency identification) solutions. The company's platform includes endpoints (tag chips), connectivity devices (readers and gateways), and software, enabling businesses to wirelessly identify, locate, and authenticate everyday items. Impinj's technology is crucial for applications in retail, supply chain management, healthcare, and logistics, helping businesses to automate inventory, track assets, and improve operational efficiency.
Read more on PI →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
